Premium
Small noncleaved follicular center cell (FCC) lymphoma: Burkitt and non‐Burkitt variants in the United States. I. Clinical features
Author(s) -
Levine Alexandra M.,
Pavlova Zdena,
Pockrosrn Ann W.,
Parker John W.,
Teitelbaum April H.,
PaganiniHill Annlia,
Powars Darleen R.,
Lukes Robert J.,
Feinstein Donald I.
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830915)52:6<1073::aid-cncr2820520624>3.0.co;2-f
Subject(s) - medicine , burkitt's lymphoma , lymphoma , virology , pathology
With the understanding that Burkitt's lymphoma was of follicular center cell (FCC) derivation, Lukes and Collins classified the tumor, descriptively, as small noncleaved FCC lymphoma. Two subtypes were described: Burkitt and non‐Burkitt. Attempting to define the clinicopathologic features of the subtypes, we studied 42 patients: 25 Burkitt and 17 non‐Burkitt. Histologically, the Burkitt tumor demonstrated remarkable uniformity of nuclear size and contour, whereas the non‐Burkitt variant had greater variability. Immunoglobulin monoclonality was demonstrated in 83% of Burkitt and 81% of non‐Burkitt cases. Burkitt patients tended to be younger. Gastrointestinal disease was seen in 15 Burkitt and only four non‐Burkitt patients ( P < 0.05). Disseminated disease was found in the majority of both variants. Marrow involvement was demonstrated in 4.5% of Burkitt and 37.5% of non‐Burkitt patients ( P < 0.05). Median survival of Burkitt patients was 10.5 months versus 7.7 months in the non‐Burkitt group. The authors believe that significant biologic differences between the variants have been demonstrated, which may be of potential value to the clinician.